Founded with the mission to revolutionize cancer treatment, SEngine Precision Medicine leverages cutting-edge 3D organoid technology and proprietary algorithms to develop next-generation cancer-targeted drugs. The company focuses on providing personalized treatment options by testing numerous cancer drugs against a patient's unique tumor organoid outside the body. This innovative approach aims to empower patients and oncologists with more informed and effective treatment options, ultimately improving patient outcomes and transforming cancer care.

SEngine Precision Medicine has garnered attention from notable investors and industry leaders in the biotech and pharmaceutical sectors. The company's high-throughput technology has led to significant advancements in personalized medicine, earning recognition for its potential to accelerate drug development and improve treatment efficacy. Through its pioneering work, SEngine has made a substantial impact on the field of oncology, offering hope for more precise and effective cancer treatments.